Company overview
Renaissance BioScience specializes in yeast bioengineering, developing innovative non-GMO and GMO yeasts for agriculture, food, animal health, and bioplastics. Key offerings include RNAi biopesticide technology targeting pests like the Colorado potato beetle, with Canadian regulatory approval for field studies, and acrylamide-reducing yeast for safer foods. The company also advances yeast-based vaccines for livestock via animal feed and partners on sustainable bioplastics for packaging and health applications.
Renaissance BioScience is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include yeast bioengineering, rnai biopesticide, acrylamide reduction, animal feed vaccines, sustainable bioplastics.
Structured facts
- Website
- https://renaissancebioscience.com
- Markets served
- United States & Americas
- Keywords
- yeast bioengineering, rnai biopesticide, acrylamide reduction, animal feed vaccines, sustainable bioplastics
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are Renaissance BioScience's core capabilities in bioengineering?
- They use whole organism and gene-targeted engineering to develop functional yeasts for agriculture, food safety, animal health, and bioplastics, including RNAi biopesticides and acrylamide-reducing strains.
- What regulatory approvals has their RNAi biopesticide technology received?
- Canadian PMRA approved their yeast-based RNAi biopesticide for 2023 field studies after reviewing extensive data, confirming low risk and efficacy against pests like Colorado potato beetle.
- What industries and geographies do they serve?
- They target global agriculture, food, animal/human health, and energy markets, with operations in Canada, field trials in multiple countries, and partnerships like the UK for bioplastics.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
